19 terminated. 19 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Terminated 19 |
| Phase 2 | 8 | Terminated 8 |
Follow Mantle Cell Lymphoma: new trials by email Literature Review of Mantle Cell Lymphoma trials Research Report on Mantle Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) 400mg of TQB3909 tablets, 600mg of TQB3909 tablets - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 19 | 2023-10-05 | 2025-12-30 |
| Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies BN301 - B-cell Lymphoma, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | BioNova Pharmaceuticals (Shanghai) LTD. | 9 | 2022-11-25 | 2024-02-21 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies PRT1419, Azacitidine, Venetoclax - Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 21 | 2022-03-22 | 2024-01-31 |
| Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL) Ublituximab, Umbralisib - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Terminated | University of Alabama at Birmingham | 1 | 2021-08-31 | 2023-09-28 |
| APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) APR-246 (eprenetapopt) + Acalabrutinib in CLL, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL, APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT - Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | Aprea Therapeutics | 1 | 2021-03-02 | 2025-03-17 |
| RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies RPM CD19-mbIL15-CAR-T cells - B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed | Phase 1 | Terminated | Eden BioCell Ltd. | 2 | 2021-03-02 | 2022-05-18 |
| Study of LUCAR-20S in Patients With R/R NHL LUCAR-20S CAR-T cells - Diffuse Large B Cell Lymphoma, Follicular Lymphoma | Phase 1 | Terminated | The First Affiliated Hospital with Nanjing Medical University | 7 | 2020-12-01 | 2022-01-10 |
| First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas GEN3009, Epcoritamab - Diffuse Large B-cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | Genmab | 46 | 2020-03-13 | 2024-10-24 |
| A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma imvotamab - Non-Hodgkin Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | IGM Biosciences, Inc. | 97 | 2019-09-30 | 2024-07-24 |
| Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Pacritinib - Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral | Phase 1 | Terminated | University of Michigan Rogel Cancer Center | 4 | 2019-05-15 | 2021-01-22 |
| Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma Loncastuximab Tesirine and Durvalumab - Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma | Phase 1 | Terminated | ADC Therapeutics S.A. | 13 | 2019-02-04 | 2021-10-26 |
| Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma Loncastuximab Tesirine, Ibrutinib - Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma | Phase 1 / Phase 2 | Terminated | ADC Therapeutics S.A. | 136 | 2018-12-01 | 2024-02-06 |
| Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies Idelalisib 100 MG, Placebo Oral Tablet - B Cells-Tumors, B Cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 16 | 2018-07-31 | 2024-03-12 |
| Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein, Autologous Hematopoietic Stem Cell Transplantation, Carmustine - Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 3 | 2017-02-01 | 2020-11-23 |
| Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma Ibrutinib, bortezomib - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Swiss Cancer Institute | 58 | 2015-08-31 | 2022-03-11 |
| Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL IMMU-114 - Non-hodgkin's Lymphoma, Follicular Lymphoma | Phase 1 | Terminated | Gilead Sciences | 30 | 2013-03-01 | 2021-08-19 |
| Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies Ublituximab, Lenalidomide - Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | TG Therapeutics, Inc. | 10 | 2012-11-21 | 2022-05-11 |
| Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma PD 0332991, bortezomib - Mantle Cell Lymphoma | Phase 1 | Terminated | Weill Medical College of Cornell University | 20 | 2010-08-23 | 2019-06-27 |
| Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia Apolizumab, Rituximab - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 35 | 2001-08-15 | 2019-12-16 |
Lymphoma, Mantle-Cell (19) · Lymphoma, Follicular (10) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, Non-Hodgkin (7) · Lymphoma, B-Cell, Marginal Zone (6) · Recurrence (5) · Lymphoma (4) · Lymphoma, B-Cell (4) · Burkitt Lymphoma (2) · Waldenstrom Macroglobulinemia (2) · Disease (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1)
Hemic and Lymphatic Diseases (19) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Lymphatic Diseases (19) · Neoplasms by Histologic Type (19) · Lymphoproliferative Disorders (18) · Neoplasms (18) · Lymphoma (15) · Disease Attributes (12) · Lymphoma, Non-Hodgkin (12) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12) · Chronic Disease (9) · Hematologic Diseases (9) · Leukemia, B-Cell (9)
Bortezomib (2) · Rituximab (2) · ibrutinib (2) · loncastuximab tesirine (2) · ublituximab (2) · venetoclax (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Azacitidine (1) · Carmustine (1) · Cytarabine (1) · DOTA-biotin (1) · Etoposide (1) · IMMU-114 (1) · Indium (1) · Lenalidomide (1)
ADC Therapeutics S.A. (2) · Aprea Therapeutics (1) · BioNova Pharmaceuticals (Shanghai) LTD. (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · Eden BioCell Ltd. (1) · Fred Hutchinson Cancer Center (1) · Genmab (1) · Gilead Sciences (1) · IGM Biosciences, Inc. (1) · National Cancer Institute (NCI) (1) · Prelude Therapeutics Incorporated (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Swiss Cancer Institute (1) · TG Therapeutics, Inc. (1) · The First Affiliated Hospital with Nanjing Medical University (1)
United States (14) · Spain (4) · China (3) · Italy (3) · Belgium (2) · France (2) · Australia (1) · Czechia (1) · Denmark (1) · Germany (1) · Netherlands (1) · South Korea (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Ajay Gopal (1) · Amitkumar Mehta (1) · Baijun Fang, Prof. (1) · Douglas Gladstone, MD (1) · Jie Jin, Prof. (1) · Joachim Gullbo, MD (1) · John P Leonard, MD (1) · Kai Hu, PhD& MD (1) · Kaiyang Ding, PhD& MD (1) · Liling Zhang, Prof. (1) · Ryan Wilcox, MD, PhD (1) · Shangru Wu, PhD (1) · Urban Novak, PD Dr. med. (1)
2018 (2), 2014 (1), 2019 (1), P01CA044991 (1), P30CA015704 (1)